Title |
Examining Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Efficacy in Managing LDL-C Levels and Reducing Cardiovascular Events |
Creator |
Shelby S. Bowman, Anthony M. Cabri, Jenelle P. Newman, and Laura M. Porter |
Subject |
Atherosclerotic cardiovascular disease (ASCVD); low-density lipoprotein; cholesterol (LDL-C); myocardial infarction (MI); proprotein convertase subtilisin/kexin type 9; (PCSK9) inhibitors; statins; MSN |
Description |
This review of literature critically examines the role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors in conjunction with current treatments to reduce cardiovascular events and mortality among patients with Atherosclerotic Cardiovascular Disease (ASCVD). Emphasizing the prevalent issue of ASCVD as a major contributor to morbidity and mortality in the United States, this review focuses on the pivotal role of low-density lipoprotein cholesterol (LDL-C) in ASCVD progression. It highlights the substantial number of patients on cholesterol lowering regimens who fail to achieve optimal LDL-C levels. The use of PCSK9 inhibitors is explored as an adjunct to current treatments or as an alternative therapeutic option, showcasing their effectiveness in lowering LDL-C levels. Additionally, the manuscript navigates the hurdles and limitations healthcare providers face in prescribing these inhibitors, offering a comprehensive review of LDL-C management in ASCVD patients and the promise of PCSK9 inhibitors. |
Publisher |
Westminster University |
Date |
2023-12 |
Type |
Text; Image |
Language |
eng |
Rights Management |
Digital copyright 2023, Westminster University. All rights reserved. |
ARK |
ark:/87278/s6mz2y6p |
Setname |
wc_ir |
ID |
2402709 |
Reference URL |
https://collections.lib.utah.edu/ark:/87278/s6mz2y6p |